News from nektar therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Aug 12, 2020, 08:00 ET Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck
Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) today announced that the first patient has been dosed in the combination therapy of the Phase...
Aug 06, 2020, 16:15 ET Nektar Therapeutics Reports Second Quarter 2020 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020. Cash and investments in marketable...
Jul 28, 2020, 18:00 ET Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020, after the close of...
Jun 04, 2020, 17:00 ET Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of...
May 29, 2020, 17:00 ET Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. ...
May 22, 2020, 08:30 ET Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin ...
May 07, 2020, 16:15 ET Nektar Therapeutics Reports First Quarter 2020 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020. Cash and investments in marketable...
Apr 28, 2020, 17:00 ET Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of...
Feb 28, 2020, 18:30 ET Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in ...
Feb 27, 2020, 16:15 ET Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019. Cash and...
Feb 18, 2020, 17:00 ET Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2019, on Thursday, February ...
Feb 03, 2020, 08:00 ET Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications
Nektar Therapeutics (NASDAQ: NKTR) today announced the publication of preclinical data on its lead immuno-oncology candidate, NKTR-214,...
Jan 14, 2020, 22:47 ET Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
Nektar Therapeutics (NASDAQ: NKTR) issued a statement today following a meeting of the Food and Drug Administration's (FDA's) Anesthetic and...
Jan 07, 2020, 09:00 ET Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 38th Annual J.P....
Dec 17, 2019, 09:00 ET Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Myriam J. Curet, M.D., as an independent director to its Board of Directors. Dr....
Dec 09, 2019, 10:05 ET Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition...
Dec 03, 2019, 09:00 ET Nektar Appoints John Northcott as Chief Commercial Officer
Nektar Therapeutics (NASDAQ:NKTR) announced today that John Northcott has joined the company in the newly-created position of Senior Vice President...
Nov 13, 2019, 17:30 ET Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on...
Nov 10, 2019, 11:00 ET Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg)...
Nov 09, 2019, 17:30 ET Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology...
Nov 06, 2019, 16:03 ET Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019. Cash and investments in...
Nov 01, 2019, 09:00 ET Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting
Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company ...
Oct 30, 2019, 17:00 ET Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of...
Oct 16, 2019, 09:00 ET Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15...
Oct 07, 2019, 09:00 ET Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell...
